KEYNOTE-C93
Start here
The interim analysis of KEYNOTE-C93 shows that first-line pembrolizumab achieved a statistically significant and clinically meaningful improvement in progression-free survival versus carboplatin plus paclitaxel in mismatch repair-deficient advanced or recurrent endometrial cancer. In the KEYNOTE-C93/GOG-3064/ENGOT-en15 trial, the pembrolizumab group had fewer overall and grade 3 or higher treatment-related adverse events. The study did not compare pembrolizumab monotherapy with the current standard of care, immunotherapy combined with chemotherapy.
Excerpted from thelancet.com
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.com[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
The interim analysis of KEYNOTE-C93 shows that first-line pembrolizumab achieved a statistically significant and clinically meaningful improvement in progression-free survival versus carboplatin plus paclitaxel in mismatch repair-deficient advanced or recurrent endometrial cancer. In the KEYNOTE-C93/GOG-3064/ENGOT-en15 trial, the pembrolizumab group had fewer overall and grade 3 or higher treatment-related adverse events. The study did not compare pembrolizumab monotherapy with the current standard of care, immunotherapy combined with chemotherapy.
Heat trend for this story
Heat now 72·Peak in the comparable set 72 (Oct 27 03:00)·Change over 24h in the comparable set –·Participants now 8
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.